BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
OPDUALAG (nivolumab and relatlimab-rmbw) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDUALAG is a dual checkpoint inhibitor combining nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) administered as a single IV infusion. It blocks both PD-1 and LAG-3 pathways to enhance T-cell activation and anti-tumor immunity. The combination approach targets patients with advanced melanoma and other solid tumors where dual checkpoint blockade may improve response rates over monotherapy.
$0.004BPart D
PeakOPDUALAG is in peak commercial phase but with modest Part D uptake ($4M, 143 claims in 2023), indicating early-stage market penetration with significant growth potential in an expanding immunotherapy landscape.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Started Sep 2026
15 enrolled
Metastatic MelanomaLiver Metastases
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Started Nov 2025
20 enrolled
Locally Advanced Melanoma
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Started Aug 2025
30 enrolled
Basal Cell Carcinoma
Career Relevance
OPDUALAG roles are concentrated in commercial execution, medical education, and market access given its peak lifecycle stage and modest current uptake. Career opportunity centers on driving adoption in a crowded checkpoint inhibitor market and establishing the dual-checkpoint mechanism as a differentiated standard, requiring strong clinical knowledge and payer strategy expertise.
Worked on OPDUALAG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.